AngioDynamics has signed an agreement with Merz North America, US affiliates of the global Merz Pharma Group. AngioDynamics is to serve as the exclusive distributor of the Asclera polidocanol injection within the US vein market.
Polidocanol is approved for the treatment of uncomplicated spider and uncomplicated reticular veins. In a multicentre, randomised, double-blind, placebo and comparator-controlled trial in patients with spider or reticular varicose veins, 95% of patients treated with the drug showed good improvement or complete treatment success as rated by physicians and 87% of patients were satisfied or very satisfied with their treatment.
“At AngioDynamics, we believe that Asclera represents the future of sclerotherapy vein treatment. Asclera offers a unique benefit for patient care,” says Joseph M DeVivo, president and chief executive officer of AngioDynamics.
“As a single-dose treatment, Asclera is an effective treatment option that simplifies the delivery of patient care for our vein customers. We are excited to partner with health care providers to ensure patients have access to this safe, effective vein treatment option and continue to provide even more value to our vein customers as part of our overall venous disease treatment plan.”
Asclera adds to AngioDynamics’ venous disease treatment options which include the market-leading VenaCure endovenous laser vein treatment system. The Merz partnership replaces previous distribution agreements.